The latest research update on BioXcel Therapeutics cuts the price target from US$10 to US$6, alongside a modest trim in the fair value estimate from $15.25 to $14.25. Bulls see this move as a ...

Detailed price information for Bioxcel Therapeutics Inc (BTAI-Q) from The Globe and Mail including charting and trades.

According to the press release statement, BXCL501 240 µg twice daily reduced opioid withdrawal symptoms compared to placebo during a seven-day methadone taper, as measured by the Short Opiate ...

Opioid use disorder is a global health crisis, affecting approximately 5.9 million adults in the U.S. The study suggested that BXCL501 may be as effective as or superior to lofexidine (Lucemyra®) for ...